- Home
- GDL vs ADAG Comparison
GDL vs ADAG Comparison
Compare GDL & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDL
- ADAG
- Stock Information
- Founded
- GDL 2006
- ADAG 2011
- Country
- GDL United States
- ADAG China
- Employees
- GDL N/A
- ADAG N/A
- Industry
- GDL Investment Managers
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- GDL Finance
- ADAG Health Care
- Exchange
- GDL Nasdaq
- ADAG Nasdaq
- Market Cap
- GDL 94.9M
- ADAG 84.4M
- IPO Year
- GDL N/A
- ADAG 2021
- Fundamental
- Price
- GDL $8.51
- ADAG $1.60
- Analyst Decision
- GDL
- ADAG Strong Buy
- Analyst Count
- GDL 0
- ADAG 3
- Target Price
- GDL N/A
- ADAG $7.67
- AVG Volume (30 Days)
- GDL 11.2K
- ADAG 55.1K
- Earning Date
- GDL 01-01-0001
- ADAG 08-12-2025
- Dividend Yield
- GDL 6.02%
- ADAG N/A
- EPS Growth
- GDL N/A
- ADAG N/A
- EPS
- GDL N/A
- ADAG N/A
- Revenue
- GDL N/A
- ADAG $103,204.00
- Revenue This Year
- GDL N/A
- ADAG $7,411.34
- Revenue Next Year
- GDL N/A
- ADAG $28.29
- P/E Ratio
- GDL N/A
- ADAG N/A
- Revenue Growth
- GDL N/A
- ADAG N/A
- 52 Week Low
- GDL $7.65
- ADAG $1.30
- 52 Week High
- GDL $8.13
- ADAG $3.16
- Technical
- Relative Strength Index (RSI)
- GDL 51.31
- ADAG 39.96
- Support Level
- GDL $8.45
- ADAG $1.47
- Resistance Level
- GDL $8.53
- ADAG $1.74
- Average True Range (ATR)
- GDL 0.06
- ADAG 0.14
- MACD
- GDL 0.00
- ADAG -0.02
- Stochastic Oscillator
- GDL 79.41
- ADAG 33.33
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.